MILELLA, MICHELE STANISLAW
 Distribuzione geografica
Continente #
NA - Nord America 2.226
EU - Europa 407
AS - Asia 212
AF - Africa 18
SA - Sud America 7
Totale 2.870
Nazione #
US - Stati Uniti d'America 2.162
IT - Italia 160
SE - Svezia 120
IN - India 90
CN - Cina 79
CA - Canada 58
SG - Singapore 31
DE - Germania 24
RO - Romania 19
FI - Finlandia 18
GB - Regno Unito 16
TG - Togo 12
BG - Bulgaria 11
IE - Irlanda 10
UA - Ucraina 10
MX - Messico 6
AR - Argentina 5
BE - Belgio 5
NL - Olanda 4
ES - Italia 3
FR - Francia 3
ID - Indonesia 3
JP - Giappone 3
BR - Brasile 2
IR - Iran 2
RS - Serbia 2
TH - Thailandia 2
UG - Uganda 2
ZA - Sudafrica 2
BJ - Benin 1
CZ - Repubblica Ceca 1
HR - Croazia 1
IL - Israele 1
PH - Filippine 1
SC - Seychelles 1
Totale 2.870
Città #
Fairfield 405
Ashburn 222
Woodbridge 192
Seattle 183
Houston 161
Wilmington 153
Cambridge 139
Chandler 123
Ann Arbor 69
San Paolo di Civitate 65
Beijing 54
Princeton 48
Ottawa 43
Rome 43
Lawrence 41
New York 34
Millbury 29
San Diego 28
Dearborn 25
Plano 17
Andover 16
Singapore 15
Boston 13
Norwalk 13
Phoenix 13
Lomé 12
Sofia 11
Dublin 10
Toronto 9
Helsinki 8
Fremont 6
Grafing 6
Bristol 5
Falls Church 5
Federal 5
Boardman 4
Bologna 4
Brussels 4
Bühl 4
Hyderabad 4
Mexico City 4
Montréal 4
Ahmedabad 3
Hefei 3
Jacksonville 3
Jakarta 3
Jinan 3
Kunming 3
Madrid 3
Pune 3
Tokyo 3
Bangkok 2
Belgrade 2
Bremen 2
Dallas 2
Edinburgh 2
Hamburg 2
Kampala 2
Madison 2
Nanjing 2
Orlando 2
San Jose 2
San Mateo 2
Southend 2
St. John's 2
Strasbourg 2
Trento 2
Washington 2
Zhengzhou 2
Afragola 1
Americana 1
Auburn Hills 1
Baotou 1
Biassono 1
Bonndorf 1
Buffalo 1
Casalbordino 1
Catania 1
Chicago 1
Cisterna Di Latina 1
Civitavecchia 1
Delhi 1
Des Moines 1
Dolianova 1
Fasano 1
Frankfurt am Main 1
Galati 1
Grezzana 1
Hangzhou 1
Henderson 1
Hendon 1
Hounslow 1
Indiana 1
Jiaxing 1
Latina Scalo 1
Laurel 1
Leawood 1
Los Angeles 1
New Delhi 1
Norwich 1
Totale 2.343
Nome #
Taxanes as primary chemotherapy for early breast cancer. Meta-analysis of randomized trials 109
Role of mTOR signaling in tumor microenvironment. An overview 95
INfluenza vaccine indication during therapy with Immune checkpoint inhibitors: a transversal challenge. the INVIDIa study 89
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells 81
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 81
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors. an important role for mutations in minor clones 81
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities 80
Renal cancer: new models and approach for personalizing therapy 80
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers 80
Targeting targeted agents. Open issues for clinical trial design 78
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance 75
Opposite roles of dopamine and orexin in quinpirole-induced excessive drinking: a rat model of psychotic polydipsia 74
P.04.4 PRESENTATION SYMPTOMS AND RISK FACTORS ARE ASSOCIATED WITH DIAGNOSTIC DELAY AND DISEASE STAGE BUT NOT WITH SURVIVAL OF PATIENTS WITH PANCREATIC CANCER 74
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 73
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy 73
Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies 73
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer 72
Clomipramine, but not haloperidol or aripiprazole, inhibits quinpirole-induced water contrafreeloading, a putative animal model of compulsive behavior. 71
A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer 71
Adjuvant treatment for resected renal cell carcinoma. Are all strategies equally negative? Potential implications for trial design with targeted agents 70
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer 69
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: Meta-analysis of randomized clinical trials 67
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis 66
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer 66
Compulsive-like effects of repeated administration of quinpirole on drinking behavior in rats 63
Early recurrence risk: Aromatase inhibitors versus tamoxifen 63
Compulsive-like effects of quinpirole on drinking behavior in rats are inhibited by substituting ethanol for water 63
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis 60
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer. Meta-analysis of randomized trials 60
Emerging pathways and future targets for the molecular therapy of pancreatic cancer 60
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients. Meta-regression analysis of randomized trials 58
Metastatic pancreatic cancer. Is there a light at the end of the tunnel? 58
Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials 57
PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? 55
Probable case of botulism: treating with a grain of salt 55
In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat 54
null 53
Targeting Chemokines and Chemokine GPCRs to Enhance Strong Opioid Efficacy in Neuropathic Pain 51
The influence of cost manipulation on water contrafreeloading induced by repeated exposure to quinpirole in the rat 47
Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program 47
Thyrotoxicosis and anorectic pills a case report 45
Impact of the media on the Poison Control Centres: the false outbreak of Loxosceles Rufescens spider bite in Italy 45
An outbreak of foodborne botulism in Rome 45
176. Viper envenomation with ocular neurotocic effects managed without antidote admiistration:a case report 39th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 21-24 May 2019, Naples, Italy 42
Heroin and its metabolites: relevance to heroin use disorder 30
Transfer of chemicals to a secondary container, from the introduction of new labelling regulation to COVID-19 lockdown: a retrospective analysis of exposure calls to the Poison Control Centre of Rome, Italy, 2017–2020 21
Accidental ingestion of nicotine solution for e-cigarettes: a case report 15
The endocrine disruptor cadmium modulates the androgen-estrogen receptors ratio and induces inflammatory cytokines in luminal (A) cell models of breast cancer 14
E-learning course improves knowledge in tobacco dependence, electronic nicotine delivery systems and heat-not-burn products in Medical School students 14
Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study 11
Self-harm by single- and multi-agent medication poisoning in a retrospective analysis of a Poison Control Center database from January 2018 to December 2022 3
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 1
Totale 3.038
Categoria #
all - tutte 6.983
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.983


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019130 0 0 0 0 0 0 0 0 0 0 75 55
2019/20201.171 49 26 115 62 148 150 144 153 134 83 70 37
2020/2021272 62 37 12 38 8 12 3 10 30 41 15 4
2021/2022496 5 26 59 23 53 16 17 54 33 37 97 76
2022/2023559 101 139 27 46 45 43 19 32 56 2 34 15
2023/2024305 21 36 12 25 28 81 10 34 2 48 8 0
Totale 3.038